Menu Search
Equities

RaQualia Pharma Inc

4579:TYO

RaQualia Pharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)558.00
  • Today's Change-4.00 / -0.71%
  • Shares traded25.20k
  • 1 Year change-25.10%
  • Beta1.1706
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year RaQualia Pharma Inc's revenues fell -34.85% from 2.92bn to 1.90bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 723.39m to a loss of 323.66m.
Gross margin84.78%
Net profit margin-29.28%
Operating margin-22.18%
Return on assets-7.77%
Return on equity-11.08%
Return on investment-8.56%
More ▼

Cash flow in JPYView more

In 2023, RaQualia Pharma Inc did not generate a significant amount of cash. Cash Flow from Financing totalled 793.45m or 41.73% of revenues. In addition the company used 718.60m for operations while cash used for investing totalled 135.37m.
Cash flow per share-18.95
Price/Cash flow per share--
Book value per share261.02
Tangible book value per share74.71
More ▼

Balance sheet in JPYView more

RaQualia Pharma Inc appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.31% of the market capitalization can be attributed to its 3.71bn and debt could be paid in full if management chose.
Current ratio3.69
Quick ratio3.55
Total debt/total equity0.659
Total debt/total capital0.3972
More ▼

Growth rates in JPY

Year on year, growth in earnings per share excluding extraordinary items dropped -143.45%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-334.89
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.